You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
CMEC Meeting 62, 8 June 2007
Complementary Medicines Evaluation Committee
Extracted ratified minutes
Public recommendation summary
This summary is posted shortly after the CMEC meeting to give quick advice of certain recommendations made by CMEC to the TGA. The TGA is yet to consider these recommendations and so this summary does not represent final decisions of TGA and should not be taken as such.
Reasons underlying these recommendations will be available after ratification of the Minutes at the next CMEC meeting. Other recommendations may be made at CMEC meetings but, because they concern confidential matters, or matters requiring further consideration by the TGA, they are not available for public disclosure.
CMEC confirms that the draft Minutes of its previous meeting (CMEC 61, 13 April 2007), as amended, are a true and accurate record of that meeting.
CMEC, having considered a preliminary safety review of Curculigo orchioides Gaertn., makes the following recommendations to the TGA:
That the root or rhizome of Curculigo orchioides is suitable for use as an ingredient in Listed medicines, with a restriction on the maximum daily dose equivalent to not more than 10 g/day.
That only the root or rhizome of C. orchioides is currently suitable for use as an ingredient in Listed medicines.
CMEC, having considered a preliminary safety review of Citrullus colocynthis Schrad. L., makes the following recommendation to the TGA:
That Citrullus colocynthis may only be included as an ingredient in Listed medicines as a homoeopathic preparation, at a potency of not less than 4X.
|Complementary Medicines Evaluation Committee meeting 62 (pdf)||87KB|